Charles Elliott Sigal - Director, Adaptimmune Therapeutics Plc

As of July 2, 2021


Charles Elliott Sigal Net Worth

  • Net worth is estimated to be at least $1.71M
  • Owns at least 367,038 units of Adaptimmune Therapeutics Plc stock

Charles Elliott Sigal Trading

  • Largest purchase of shares was 45,000 units , worth over $68.7K on May 18, 2016
  • In total has made about 8 transactions over 5 years
  • Usually trades in July, with the busiest year in 2016
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Charles Elliott Sigal Mailing Address

  • Mailing address is 32 Brearly Road Princeton NJ 08540 NJ

Adaptimmune Therapeutics Plc Executive Compensation

Name
Year
Salary
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Adrian Rawcliffe 2020 $574,000 $1,715,346 $378,840 $33,416 $2,701,602
Adrian Rawcliffe 2019 $500,481 $1,427,399 $177,251 $49,912 $2,155,042
Adrian Rawcliffe 2018 $457,011 $730,791 $174,807 $54,775 $1,417,384
Gavin Wood 2020 $337,065 $990,268 $166,847 $73,731 $1,567,911
Helen Tayton-Martin 2020 $454,940 $857,661 $225,195 $23,531 $1,561,327
Helen Tayton-Martin 2019 $435,949 $766,900 $137,324 $30,491 $1,370,664
Helen Tayton-Martin 2018 $408,308 $730,791 $156,178 $22,007 $1,317,284
William Bertrand 2020 $443,456 $857,661 $219,511 $30,485 $1,551,113
William Bertrand 2019 $432,640 $766,900 $136,282 $35,358 $1,371,180
William Bertrand 2018 $416,000 $685,114 $159,120 $35,070 $1,295,304
John Lunger 2020 $400,000 $857,661 $198,000 $31,802 $1,487,463
John Lunger 2019 $366,867 $435,546 $94,542 $35,655 $932,610
John Lunger 2018 $316,958 $602,909 $92,948 $35,07 $1,047,885
Michael Garone 2020 $217,000 - - - $217,000
Michael Garone 2019 $206,500 - - - $206,500
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1621227/000110465921047833/tm212433-2_def14a.htm

Adaptimmune Therapeutics Plc Insider Trading

  • The most recent transaction was 2,939 units sold on August 2, 2021 by John Lunger worth over $10.54K
  • In the last 5 years, insiders at Adaptimmune Therapeutics Plc sold an estimated value of $39.87M and bought an estimated value of $526.76M
  • The most active traders are Adrian Rawcliffe, Chief Executive Officer,  David M Mott, Director,  and John Lunger, Chief Patient Supply Officer
  • Insider trading is most common in January, with the busiest year in 2018

Adaptimmune Therapeutics PLC Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1